Urological Devices – Market Insights – Japan

The Japanese urological device market will continue to expand through 2034, driven by the rising prevalence of risk factors for urological disorders, such as the growing burden of metabolic syndrome and Japan’s large aging population. Additionally, increasing adoption of premium technologies and the wider availability of minimally invasive treatment options will bolster ASPs and contribute to revenue growth. However, market expansion will be partially constrained by Japan’s complex regulatory environment, which will limit the introduction and uptake of new premium-priced devices to some extent.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for urological devices in Japan from 2019 through 2034.

Internationally, a great deal of negative publicity has emerged surrounding the safety of synthetic mesh products.

How has negative publicity changed the UI device segment in Japan?

How will this impact Japan’s genitourinary mesh market?

Positive changes in reimbursement have influenced the adoption of premium-priced urological devices in Japan.

Which markets are most affected by these reimbursement changes?

What impact has this change had on physician preferences?

The markets for capital equipment, such as holmium laser systems and ESWL systems, have essentially reached saturation in Japan.

What are some factors that particularly impact the Japanese market for these devices?

What is the revenue outlook for these devices?

How many of these devices are currently installed in Japan, and how many new units will be installed through the forecast period?

Ongoing clinical studies and research continue to affect procedure trends, and thus device trends.

What do recent studies indicate regarding the outlook of existing techniques for treating prostate cancer, kidney stones, and BPH?

What upcoming novel treatments are expected to compete with existing methods of treatment?